Rua Life Sciences Share Discussion Threads

[bones] 24/7/2024 14:56

Significant shareholder list updated as of 30th June 2024, included in header post.

[bones] 24/7/2024 13:33

I think we are done with 2m losses. Two full board members and a good number of employees left the company during H2 to 31/3 and a lot less generally was spent in H2. There will have been one off payoffs as well to many of those.

Prior to that, most of the major expenses over the last few years have been on the vascular graft development and that cost has the potential to be recovered if they can get a partner to take on the clinical trial stage.

[cfb2] 24/7/2024 12:27

Good to see a contract win with a high profit margin but RUA need to be achieving this level every month to become profitable and cut the fat.

Around a year ago I said they need to strip away anything that BB has added if they have given up on products. They've now got 2 years to do it.

[the surgeon] 24/7/2024 11:44

More losses and hardly any growth. What’s to be done when the money runs out entirely. Another fund raising? Unlikely to get another off the ground. Cannot trade under the rules if il-liquid.

[amt] 24/7/2024 11:01

The IP wasn't worth as much as hoped after twenty years so somewhat disappointing but now a steady business with upside but not with stellar upside once hoped for.

[obiterdicta] 24/7/2024 10:27

Bit touchy and rude. Concede the possibility that the corner may have been turned, just look blinkered otherwise.

[obiterdicta] 24/7/2024 10:06

Second RNS does not look too shabby. Humble pie may be due for some posters.

[cocker] 24/7/2024 09:38

Amazing, two ticks down for my last post, well the pair of you can perhaps speak up and tell us all what is so great about the results and what's in them. From where I'm standing, anything remotely positive would have had at the very least a few mentions,but nowt says it all.

[bones] 23/7/2024 16:23

I’m not convinced that is new data, ENW. Do you have the link handy?

I remember reading about RIM on one of the RUA websites several years ago, perhaps as more general info about what could be possible with Elast-Eon. If anyone is to progress it, I would think that would be Biomerics under licence from RUA as they currently are.

It’s not part of RUA’s current strategy to be trying out more new areas of R&D and manufacturing on their own ticket as they’ve said the three areas of focus now are marketing the contract manufacturing, heart valve material and finding a partner for the Vascular project.

But, I could be wrong! Maybe something gets said in the forthcoming results.

[early not wrong] 23/7/2024 13:40

From the RUA website: Must have missed this development.

Elast-EonTM Reaction Injection Molding

Elast-EonTM has been adapted for use with Reaction Injection Molding (RIM) to provide new and advantageous ways to make many medical devices. This new product will be sold as a two part reactive liquid system.

RIM processing has existed in high volume, high throughput manufacturing operations such as automotive and aerospace for decades. Typical applications include dashboards, bumpers and overhead bin panels.

The RUA Biomaterials team has developed Elast-EonTM and RIM technology for use in high-precision medical device components. This novel adaptation has resulted in the filing of new patent applications and has recently received considerable attention from some of the world’s largest medical device companies.

Some key advantages of Elast-EonTM and RIM
High bond strength to substrates, typically 2500 psi or better to titanium
Rapid molding cycles (typically 2 minutes)
Low molding temperatures, typically 40-50 degrees C
Low molding pressures due to low typical viscosities of 5000 centipoise
Elast-EonTM performance (mechanical properties and biological stability)
Manufacturing efficiency
Device designers are now taking advantage of Elast-EonTM and RIM to dramatically increase bond strengths or to create new products containing sensitive electronics and/or batteries that traditional injection molding would damage.

Medical manufacturing specialists are now starting to implement the Elast-EonTM and RIM technology to reduce the costs of producing devices and increase efficiency.

The first Elast-EonTM and RIM devices are moving toward human use in Neurostimulation devices, however, there is considerable interest for use in pacemaker headers, orthopaedics and spinal devices.

[bones] 25/6/2024 19:29

Ross McPhillie up in lights on RUA Medical’s website. They really should be flinging this around the medical fraternity and publicising it.

[amt] 20/6/2024 09:34

Reward for failure. The options should have been priced above the market price

[harrogate] 20/6/2024 08:37

If this reorganisation and option grant signals things are happening then I am all for it. It is unrealistic to expect management to sit there and say that because they messed up they have to miss out on what are fairly standard incentives. I am not yet convinced that they will find anyone to take on the graft project in a way that provides value now and remain if the view that the HV is our only chance of a decent return. Let's hope the bench results at RUA match what they major is seeing in their work

[thiopia] 19/6/2024 22:46

Concur with that opinion. They'll have priced the option or timed it so its a short term low so this should act as a signal to the market as well as under pin us here.

They must be fairly well advanced in any negotiations so will have a fair idea of upcoming newsflow over next few weeks/months.


I'd be looking to accumulate here.

[bones] 19/6/2024 21:00

I’m fine with any options which are priced at the market when granted. So many AIM and other company boards punt them out at nil paid or fractions of the market price.

We’ll have to disagree on it. I’ll take the view that this move wouldn’t have been made if there wasn’t a good chance something will happen down the line to make the options worthwhile at today’s price. They got it wrong with trying to go it alone with grafts but I think it’s a more realistic strategy to expand contract manufacturing while trying to sell or licence the developed technologies.

[cocker] 19/6/2024 19:16

Getting their options in ahead of such possibilities. What you really mean to say is that "IF" it comes off, then these parasites have made sure that they are fully loaded and will be heavily rewarded.